Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Industry News

Study: SelectMDx cost-effective in four European countries

Aug. 30, 2018—MDxHealth announced that a study validating the cost-effectiveness of SelectMDx for Prostate Cancer has been published in Prostate Cancer and Prostatic Diseases (Govers TM, et al. Epub ahead of print Aug. 20, 2018. doi:10.1038/s41391-018-0076-3). The study evaluates the potential cost-effectiveness of SelectMDx, a noninvasive liquid biopsy test to identify patients at increased risk of aggressive prostate cancer, in a population of men from France, Germany, Italy, and Spain with elevated prostate specific antigen. The model used in the study

Agena, PerkinElmer team up

Aug. 24, 2018—Agena Bioscience announced it has entered into a collaboration with PerkinElmer, incorporating the LabChip GX Touch nucleic acid analyzer for quality assessment and quantitation of DNA in the upfront workflow of Agena’s MassArray system. The companies have focused on targeting ctDNA in oncology liquid biopsy, where the combined systems aim to support a low cost, highly robust, single-day sample-to-results workflow for laboratories. PerkinElmer’s LabChip GX Touch nucleic acid analyzer provides electrophoretic visual quality assessment and quantitation down to

Sysmex enhances customer training with new learning center

Aug. 23, 2018—Sysmex has opened a state-of-the-art 98,000-square-foot Center for Learning in Vernon Hills, Ill. The multimillion-dollar facility provides a training environment for 3,000 customers—who will be taught virtually and on site—and 1,400 Sysmex employees annually. It has more than triple the training capacity of the previous Center for Learning, with two conventional classrooms for laboratory professionals and six classrooms for Sysmex technical engineers, the company reports. The facility also houses seven broadcast studios for virtual instructor-led training. The studios

Techlab gets FDA clearance for H. pylori tests

Aug. 22, 2018—Techlab received FDA 510(k) clearance for its H. Pylori Quik Chek and H. Pylori Chek tests. The tests aim to offer quick and reliable detection of Helicobacter pylori–specific antigen in human fecal specimens. The H. Pylori Quik Chek test is a rapid diagnostic test that detects H. pylori in 30 minutes. The H. Pylori Chek test is a 96-well plate format diagnostic for laboratories testing large numbers of specimens and can be performed with or without automation in one hour.

Precision medicine conference to take place Sept. 12–13

Aug. 21, 2018—Precision medicine strategies and successes in improving patient outcomes are key themes when hospital and health network CEOs and administrators gather in Nashville Sept. 12–13 to hear from innovators at Vanderbilt University Medical Center, Geisinger Health, Northwell Health, Moffitt Cancer Center, and Seattle Children’s Hospital, among others.

Study: DCISionRT predicts radiation therapy benefit

Aug. 9, 2018—Prelude Corp. announced that Clinical Cancer Research published results from a large cross-validation study of DCISionRT in patients with ductal carcinoma in situ (Bremer T, et al. Epub ahead of print July 27, 2018. doi:10.1158/1078-0432.CCR-18-0842). The multisite study demonstrated that DCISionRT was a strong predictor of radiation benefit and was able to identify patients with significantly elevated recurrence risk that would be considered low risk by traditional clinical assessment. “The study analyzed the biology and clinical factors of

Beckman releases DxM MicroScan

Aug. 7, 2018—Beckman Coulter announced commercialization of its DxM MicroScan WalkAway system, a diagnostic solution for bacterial identification and antibiotic susceptibility testing that uses direct minimum inhibitory concentrations for detection of antimicrobial resistance. The system’s delivery of gold-standard MIC accuracy helps laboratories achieve their operational goals by reducing costs associated with confirmatory testing, the company says. Added workflow enhancements include a new fluid-level sensing technology for added assurance, easy-to-view external LED indicators that show status at a glance, quick bottle

Sysmex, Advanced Instruments offer CSF cell counter

Aug. 6, 2018—Sysmex America and Advanced Instruments announced a partnership that will broaden the Sysmex portfolio with Advanced Instruments’ automated GloCyte cell counter system. The GloCyte system uses a combination of fluorescence, microscopy with digital image analysis, highly specific reagents, and an intelligent counting algorithm to provide accurate counts down to zero for both red blood cell and total nucleated cell in cerebrospinal fluid in adult and pediatric patients. “The addition of GloCyte makes our portfolio of diagnostic analyzers even

FDA approves Cobas HPV Test with SurePath

Aug. 3, 2018—Roche has received FDA approval for the Cobas HPV Test to be used as the first-line screening test for cervical cancer in women 25 and older using specimens collected in SurePath preservative fluid. The Roche test is now the only HPV test approved for use as a primary screening test with both SurePath and ThinPrep PreservCyt Solution. It is approved for all of the cervical cancer screening indications supported by guidelines—primary screening in women 25 and older, reflex

MedTest chem assays, hematology analyzer

Aug. 2, 2018—MedTest Dx introduced its BA-800M Clinical Analyzer for general chemistry with a full line of reagents and launched its BC-5390 5-Part Differential Hematology Analyzer at the 2018 American Association for Clinical Chemistry Annual Scientific Meeting, in Chicago. The MedTest Dx BA-800M is a fully automated, discrete random-access chemistry analyzer designed for mid- to large-volume clinical testing laboratories now available with reagents manufactured in the U.S. in a GMP-regulated and ISO 13485-certified environment. The BA-800M has a throughput of

MARKETPLACE

TRENDING